These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29679749)

  • 1. Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week.
    Coyle PK; Shang S; Xiao Z; Dong Q; Castrillo-Viguera C
    Mult Scler Relat Disord; 2018 May; 22():134-138. PubMed ID: 29679749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
    Newsome SD; Mokliatchouk O; Castrillo-Viguera C; Naylor ML
    Mult Scler Relat Disord; 2020 May; 40():101954. PubMed ID: 32078948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.
    Newsome SD; Kieseier BC; Arnold DL; Shang S; Liu S; Hung S; Sabatella G
    J Neurol; 2016 Sep; 263(9):1778-87. PubMed ID: 27314959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY).
    Shaygannejad V; Ashtari F; Saeidi M; Beladi Moghadam N; Ghalyanchi Langroodi H; Baghbanian SM; Abolfazli R; Ghiasian M; Ayromlou H; Asadollahzadeh E; Sabzvari A; Kafi H; Azimi Saeen A
    Mult Scler Relat Disord; 2024 Oct; 90():105839. PubMed ID: 39217809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
    Kieseier BC; Arnold DL; Balcer LJ; Boyko AA; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A; Sheikh SI; Calabresi PA
    Mult Scler; 2015 Jul; 21(8):1025-35. PubMed ID: 25432952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN.
    Newsome SD; Scott TF; Arnold DL; Altincatal A; Naylor ML
    Mult Scler Relat Disord; 2022 Jan; 57():103367. PubMed ID: 35158473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
    Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
    BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis.
    Hoy SM
    CNS Drugs; 2015 Feb; 29(2):171-9. PubMed ID: 25666445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
    Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
    BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study.
    Arnold DL; You X; Castrillo-Viguera C
    J Neurol; 2017 Aug; 264(8):1728-1734. PubMed ID: 28685353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
    Hernandez L; Guo S; Toro-Diaz H; Carroll S; Syed Farooq SF
    J Med Econ; 2017 Mar; 20(3):228-238. PubMed ID: 27730845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.
    Ernst FR; Barr P; Elmor R; Wong SL
    Curr Med Res Opin; 2017 Dec; 33(12):2099-2106. PubMed ID: 28906152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
    De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
    J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
    Dashputre AA; Kamal KM; Pawar G
    J Manag Care Spec Pharm; 2017 Jun; 23(6):666-676. PubMed ID: 28530523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis.
    Newsome SD; Guo S; Altincatal A; Proskorovsky I; Kinter E; Phillips G; You X; Sabatella G
    Mult Scler Relat Disord; 2015 Jul; 4(4):350-7. PubMed ID: 26195056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.